Animal Testing and the 3Rs: Reduction

 

Dr. Shoebul Haque is a dynamic young pharmacologist currently serving as an Assistant Professor of Pharmacology at Era’s Lucknow Medical College and Hospital, Lucknow, India. 

He completed his MD in Pharmacology from King George’s Medical University, Lucknow, and holds postgraduate diplomas in Maternal & Child Health and Infectious Diseases, along with certifications in biomedical research, ethics, and pharmacovigilance.

 With over 35 research publications and the authorship of the book Drug Tales and Therapeutic Frontiers, his academic interests span clinical and experimental pharmacology, medical writing, drug safety, and innovative teaching methodologies in medical education. 

He is a certified reviewer, editorial board member, and an active member of national and international pharmacology societies. His current research, approved by the Institutional Ethics Committee (IEC), focuses on the application of gaming and interactive learning strategies in pharmacology education, alongside prior CCSEA-approved work evaluating drug effects in animal models with an emphasis on ethical and scientifically responsible preclinical studies.

Hannah gained a 1^st class degree in Pharmacology from the University of Leeds, including a 12 month placement in the pharmacology department at the Novartis Institute for Tropical Disease.

She then went on to complete a Master’s degree focused on cancer biology at UCL. Since leaving academia, Hannah currently works as a Senior Medical Writer in a London-based healthcare communications agency. 

She has a continued interest in scientific communication, particularly the dissemination of complex health concepts to lay audiences. 

Animal Testing and the 3Rs: Reduction

In our ongoing exploration of the 3Rs (Replacement, Reduction, and Refinement), we now turn our focus to the principle of Reduction. While animal models have historically played a crucial role in understanding biology and developing new treatments, the ethical and scientific community continues to search for ways to balance scientific progress with responsible use of animals. Reduction is not about halting research altogether but about using the minimum number of animals necessary, while maximizing the quality and relevance of the data produced.^[1] This article will examine the concept of Reduction, highlight innovative strategies being implemented in laboratories worldwide, and reflect on how these practices enhance both science and animal welfare.

What is Reduction?

Reduction refers to the design and execution of experiments that minimize the number of animals used, without compromising scientific integrity. The principle ensures that every study is necessary, well-planned, and capable of producing robust, reproducible results.^[2] It is not simply about cutting numbers for the sake of ethics; it is about striking a balance between efficiency, quality, and humanity. The NC3Rs frames Reduction as an opportunity to gain as much valuable information as possible from each animal, while also developing tools and methods that enable scientists to achieve reliable results with fewer subjects. Importantly, poorly designed experiments that use too few animals or lack statistical power can be just as ethically questionable as those that use too many.^[1] Thus, Reduction hinges on better planning, smarter use of technology, and methodological innovation.

 

 

 

 

Reduction can be applied at different levels. At the intra-experimental level, careful design, the use of pilot studies, and prior data analysis help minimize the number of animals per experiment. At the supra-experimental level, awareness and training in robust methodology encourage researchers to apply reduction practices consistently. Finally, at the extra-experimental level, clearer practices such as international harmonisation of guidelines (e.g., OECD Test Guidelines), mutual acceptance of data by regulatory agencies, and global data-sharing initiatives help prevent unnecessary duplication of studies across countries, thereby further reducing overall animal use.^[3]

Smarter Experimental Design

One of the most impactful ways to achieve Reduction is through robust experimental design. Tools such as power calculations and statistical modelling help researchers determine the minimum number of animals required to achieve meaningful results.^[4] Adaptive trial designs, where experiments evolve based on interim data, further reduce unnecessary repetition. By carefully considering control groups, endpoints, and statistical methods before starting a study, researchers avoid wasting animal lives on experiments that lack rigour or cannot contribute to the broader body of knowledge. The NC3Rs has also developed platforms like the Experimental Design Assistant (EDA), an online tool that helps researchers design, plan, and review experiments with a focus on reducing animal numbers while maximizing reproducibility.^[5]

 

Figure: Experimental Design Assistant (EDA), online tool https://eda.nc3rs.org.uk/

Maximizing Data Per Animal

Another core element of Reduction involves gathering the maximum amount of useful data from each animal. This is achieved by integrating multiple technologies and procedures into a single study. For example, non-invasive imaging techniques such as MRI, PET, and CT scanning allow researchers to monitor disease progression and treatment responses in the same animal over time, eliminating the need for multiple cohorts.^[6] Similarly, microsampling techniques enable repeated blood analysis from the same subject, minimizing the need to sacrifice additional animals for toxicological or pharmacokinetic studies.^[7]

Tissue-sharing initiatives also contribute to Reduction. If one study does not utilize all tissues or organs collected, these can be ethically and systematically shared with other research groups, ensuring no material goes to waste.^[8]

Technological Advances Driving Reduction

Modern technology continues to transform how researchers reduce reliance on large numbers of animals. Some notable examples include:

• Biobanks: Collections of ethically sourced animal and human tissues provide opportunities to test hypotheses without the need for fresh animal experimentation.^[9]
• Wearable devices: Miniaturised sensors that monitor heart rate, activity, or temperature in real time reduce the number of animals needed to track physiological changes. A study Implantation of radiotelemetry transmitters yielding data on ECG, heart rate, core body temperature, and activity in free‑moving laboratory mice describes how implanted telemetry transmitters enable continuous measurements of physiological parameters (heart rate, ECG, temperature, activity) in freely moving, untethered mice. This reduces variability and allows more data from fewer animals.^[10]

• Machine learning and big data: By analysing past datasets, predictive models can be built, reducing duplication of studies and unnecessary repetition. A review of current trends and future perspectives reviews how machine learning and big data approaches, integrating large datasets (omics, chemical properties, historical toxicology data), help predict adverse drug reactions and avoid redundant or unnecessary animal experiments.^[11]

 

Recent AI, Digital Twin, and Organ-on-Chip Developments Enabling Reduction

In addition to these advances, several cutting-edge technologies have recently demonstrated major potential for reducing animal use. A 2025 review highlighted how AI-driven digital twins, when combined with organ-on-chip (OoC) systems, can simulate drug responses, predict toxicity, and model human-specific physiology with high accuracy, allowing early-stage screening to shift away from animal models.^[12] These AI-supported in-silico and microphysiological systems enable researchers to test dosing, toxicity, and pharmacokinetics virtually or on human-derived chips, thereby reducing the number of in vivo studies required. Such approaches not only enhance Reduction but also improve translational relevance by providing human-specific data.

Toxicology Testing

Toxicology, a field traditionally dependent on large-scale animal studies, has seen major advances in Reduction. Regulators and researchers now increasingly use integrated approaches such as toxicogenomics (studying changes in gene expression) and high-content screening assays, which allow multiple endpoints to be measured from fewer animals.^[13] Combined with in vitro and in silico data, these methods not only reduce animal numbers but also improve human relevance. For example, recent work in drug-induced liver injury (DILI) prediction has demonstrated that microphysiological “liver-on-chip” platforms, combined with AI-based toxicity modelling, can reliably forecast hepatotoxicity of small-molecule drugs, reducing the need for large rodent cohorts in early-stage safety pharmacology.^[14] This success highlights how modern integrated toxicology approaches are already contributing to meaningful reductions in pharmacological research.

Reduction as a Pillar of Ethical Science

Reduction is not simply about statistics; it reflects a broader commitment to ethical responsibility. By ensuring that each animal study is justified, well-designed, and data-rich, researchers both respect animal welfare and elevate the scientific value of their work. Poorly designed experiments that waste animal lives damage trust in science, while robust reduction practices enhance reproducibility and credibility.

 

Concluding Remarks

The principle of Reduction, alongside Replacement and Refinement, offers a roadmap for responsible animal research. Reduction sits at the core of ethical and modern animal research, reminding us that scientific progress and compassion are not opposing forces but complementary responsibilities. As this article demonstrates, meaningful Reduction is achieved not by limiting discovery, but by elevating the quality of experimental design, embracing advanced technologies, and fostering global collaboration. From microsampling and imaging innovations to AI-driven digital twins and organ-on-chip platforms, researchers now have a growing toolbox that allows more information to be obtained from fewer animals, often with greater accuracy and human relevance.

Ultimately, Reduction is an ongoing commitment rather than a static guideline. It requires continuous reflection, methodological rigor, and openness to emerging alternatives. By integrating Reduction thoughtfully at every stage of research, from planning to execution and data sharing, the scientific community can uphold both ethical standards and scientific excellence. In doing so, we not only safeguard animal welfare but also strengthen the reliability, transparency, and global trust in biomedical research.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

References

1. Boo J De, Hendriksen C. Reduction Strategies in Animal Research : A Review of Scientific Approaches at the Intra-experimental, Supra-experimental and Extra-experimental Levels. ATLA 2005;(4):369–77. 
2. Strech D, Dirnagl U. 3Rs missing : animal research without scientific value is unethical. BMJ 2019;3:1–4. 
3. Verderio P, Lecchi M, Ciniselli CM, Shishmani B, Apolone G, Manenti G. of Animal Research. animals 2023;13:1–14. 
4. Karp NA, Fry D. What is the optimum design for my animal experiment ? BMJ 2021;5:1–18. 
5. Percie N, Bamsey I, Bate ST, Berdoy M, Clark RA, Cuthill I, et al. The Experimental Design Assistant. PLOS Biol [Internet] 2017;1–9. Available from: doi.org/10.1371/journal.pbio.2003779
6. Tremoleda JL. Reducing The Number Of Research Animals : How Imaging Technologies Can Help. Front young minds 2022;10:1–8. 
7. Prior H, Adedeji AO, Allen R, Angus D, Baker D, Blunt H, et al. Microsampling in toxicology studies-maximising the scientific, business and 3Rs advantages. Toxicol Res (Camb) 2025;14(2). 
8. Park G, Alice Y, Sohn Y, Nam Y, Ju JH. Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations. Stem Cell Rev Reports 2024;20:1375–86. 
9. Malsagova K, Kopylov A, Stepanov A, Butkova T, Sinitsyna A, Izotov A, et al. Biobanks — A Platform for Scientific and Biomedical Research. Diagnostics 2020;485:2–21. 
10. Cesarovic N, Jirkof P, Rettich A, Arras M. Implantation of radiotelemetry transmitters yielding data on ECG, heart rate, core body temperature, and activity in free-moving laboratory mice. J Vis Exp 2011;(57):1–7. 
11. Ajisafe OM, Adekunle YA, Egbon E, Ogbonna CE, Olawade DB. The role of machine learning in predictive toxicology: A review of current trends and future perspectives. Life Sci [Internet] 2025;378(June):123821. Available from: doi.org/10.1016/j.lfs.2025.123821
12. Möller J, Pörtner R. Digital Twins for Tissue Culture Techniques; Concepts, Expectations, and State of the Art. Processes 2021;9:2–24. 
13. Pandiri AR, Auerbach SS, Stevens JL, Blomme EAG. Toxicogenomics Approaches to Address Toxicity and Carcinogenicity in the Liver. Toxicol Pathol 2023;51(7–8):470–81.
14.  Novac O, Silva R, Young LM, Lachani K, Hughes D, Kostrzewski T. Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro. J Vis Exp 2022;2022(179):1–18.